Inavolisib, in combination with palbociclib (CDK4/6 inhibitor) and fulvestrant (estrogen-receptor antagonist), is approved for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative breast cancer [83]. This evidence concerns the gene ERBB2 and breast carcinoma.